Peter F. Orio III, DO, MS, presented “Biomarkers for Radiation Therapy” during the 24th Future Directions in Urology Symposium in August 2024 in Colorado Springs, Colorado.
How to cite: Orio III, Peter F. “Biomarkers for Radiation Therapy.” August 2024. Accessed Nov 2024. https://grandroundsinurology.com/biomarkers-for-radiation-therapy/
Biomarkers for Radiation Therapy – Summary
Peter F. Orio III, DO, MS, focuses on the evolving role of biomarkers in radiation oncology, particularly for prostate cancer. He asserts that biomarkers serve as biological indicators that help predict and monitor responses to treatment, thereby optimizing therapeutic outcomes and reducing toxicity.
In this 12-minute presentation, Dr. Orio categorizes radiation biomarkers into diagnostic, predictive, prognostic, and monitoring types, emphasizing their distinct roles in disease prediction, treatment response, and patient prognosis. Orio provides examples and discusses how these tools influence radiation planning and decision-making across various medical disciplines, including radiation oncology, medical oncology, and surgery.
The presentation underscores that while many biomarkers are prognostic, the future lies in their predictive capabilities, which are crucial for truly personalized treatment.
The Future Directions in Urology Symposium (FDUS) is an annual urology think tank and non-CME educational summit that brings together industry figures and experts to discuss the current state of genitourinary care and define future directions in treatment. Dr. Dreicer delivered this educational activity during the 24th iteration of the meeting in August 2024 in Colorado Springs, Colorado.
ABOUT THE AUTHOR
Peter F. Orio III, DO, MS, is Vice Chair of Network Operations for the Dana Farber Brigham Cancer Centers in Boston, Massachusetts. He also serves as the Director of Prostate Brachytherapy for the Dana Farber Brigham Cancer Centers and is an Associate Professor at Harvard Medical School. Dr. Orio earned his Bachelor of Arts in Biology/Psychology from the College of the Holy Cross, his Master’s of Science in Public Health from the University of Massachusetts at Amherst and his Doctor of Osteopathic Medicine degree from the University of New England College of Osteopathic Medicine. He completed his residency in radiation oncology at the University of Washington Medical Center. Dr. Orio served in the US Army as Assistant Chief of Radiation Oncology at Brooke Army Medical Center, where he rose to the rank of Lieutenant Colonel. Dr. Orio is active in the American Brachytherapy Society (ABS) and the American Society for Radiation Oncology (ASTRO), focusing his efforts on the advancement of brachytherapy for prostate cancer and the socioeconomics of medicine.
